Financial Report: Teva

Teva
 
4Q Revenues: $5.2 billion (-5%)

4Q Earnings: $694 million (+84%)

FY Revenues: $20.3 billion (flat)

FY Earnings: $3.0 billion (+142%)

Comments: Generic revenues were $2.5 billion in the quarter, down 8%. U.S. revenues were flat at $1.2 billion. European revenues were $759 million, down16%, with lower revenues in Germany, France and Spain. ROW revenues were $532 million, down 12%. API sales to third parties were $178 million, up 2%. Copaxone sales were $1.1 billion, down 2% in the quarter. Azilect sales were 108 million, up 10%. Treanda sales were up 28% to $226 million. ProAir sales were up 5% to $120 million. Women’s Health sales were down 14% to $115 million.Specialty Medicinesrevenue was 2.2 billion, up 1%. U.S. sales were $1.6 billion, up 6%. European revenues were $448 million, down 11%, and ROW revenues amounted to $167 million, down 2%.